Related Experiment Video

Updated: Apr 18, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

13.0K

Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy

Yoriko Yamashita1

  • 1Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan k46581a@nucc.cc.nagoya-u.ac.jp.

Japanese Journal of Clinical Oncology
|January 14, 2015
PubMed

Insights

Ovarian clear cell carcinoma, often resistant to chemotherapy, is increasingly understood through its molecular features like PI3CA and ARID1a mutations. Research also explores its link to endometriosis and potential new treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gynecologic Pathology

Background:

  • Ovarian clear cell carcinoma (OCCC) historically presents with poor prognosis due to chemoresistance.
  • Recent research has identified key molecular alterations in OCCC, including PI3CA mutations, ARID1a mutations, and MET amplification.
  • An emerging focus is the association between OCCC and endometriosis.

Purpose of the Study:

  • To review the specific molecular changes in OCCC.
  • To discuss the significance of these molecular alterations and unresolved questions.
  • To explore future therapeutic strategies for OCCC.

Main Methods:

  • Literature review of recent studies on OCCC molecular characteristics.
  • Analysis of published data on PI3CA, ARID1a, and MET alterations.
  • Synthesis of information regarding the endometriosis-OCCC link and therapeutic developments.

Main Results:

  • OCCC is characterized by specific molecular drivers (PI3CA, ARID1a mutations, MET amplification).
  • The relationship between endometriosis and OCCC is a significant area of investigation.
  • Understanding these molecular aspects is crucial for improving patient outcomes.

Conclusions:

  • Molecular profiling is essential for understanding OCCC pathogenesis and chemoresistance.
  • Further research into the endometriosis association may reveal novel insights.
  • Targeted therapies based on identified molecular alterations hold promise for future OCCC treatment.
Keywords:
ARID1A mutationMET amplificationPI3CA mutationovarian clear cell carcinomatargeted therapy

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

3.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K